Publicaciones en colaboración con investigadores/as de University of Pennsylvania (10)

2024

  1. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma

    The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216

2023

  1. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

2021

  1. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

    Leukemia, Vol. 35, Núm. 1, pp. 18-30

  2. The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma

    Transplantation and Cellular Therapy, Vol. 27, Núm. 10, pp. 807-816

  3. The Nuclear Receptor ESRRA Protects from Kidney Disease by Coupling Metabolism and Differentiation

    Cell Metabolism, Vol. 33, Núm. 2, pp. 379-394.e8

2020

  1. Repurposing the yellow fever vaccine for intratumoral immunotherapy

    EMBO Molecular Medicine, Vol. 12, Núm. 1

2017

  1. Arterial spin labeling MRI is able to detect early hemodynamic changes in diabetic nephropathy

    Journal of Magnetic Resonance Imaging, Vol. 46, Núm. 6, pp. 1810-1817

2016

  1. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

2015

  1. The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development

    Nature Medicine, Vol. 21, Núm. 10, pp. 1199-1208

2014

  1. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

    The Lancet Oncology, Vol. 15, Núm. 12, pp. e538-e548